This review summarizes and analyzes the clinical outcomes following treatment of a wide range of diseases with recombinant interferons (r-IFNs) and/or natural interferons (n-IFNs). The investigation focuses on the frequency of neutralizing antibodies (NABs) directed against IFN, which are formed during treatment and their clinical impact. r-IFNs (α-2a, α-2b, β-1a, and β-1b) induced seroconversion with generation of NABs in 17.2% of patients studied. The highest incidence of NABs occurred in macular degeneration (61.4%) with the lowest in multiple sclerosis (14.7%). The incidence of antibodies induced against n-IFNs was very low (<0.2%) and was significantly less than that seen for r-IFNs (P<0.0001). Overall, the fraction of relapsed and refractory patients is statistically greater in NAB positive patients compared to NAB negative patients (<0.0001), whereas the percentage of responding patients is higher in the NAB negative cohort (P<0.001). Finally, we also analyzed relapsed and refractory NAB positive patients who switched treatment to n-IFN, such as leukocyte derived Alferon N Injection® (α-n3) or Wellferon® (α-n1). Overall, in 33/40 (82%) of these relapsed or refractory patients, switching to n-IFNs restored the clinical response. This result is consistent with serology studies showing that the NABs directed against r-IFNs do not effectively cross-react with n-IFNs.
Get full access to this article
View all access options for this article.
References
1.
AntonelliG, GiannelliG, CurrentiM, SimeoniE, Del VecchioS, MaggiF, PistelloM, RoffiL, PastoreG, ChemelloL, DianzaniF. 1996. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapy. Clin Exp Immunol, 104:384–387.
2.
AntonelliG, SimeoniE, BagnatoF, PozzilliC, TurrizianiO, TesoroR, Di MarcoP, GasperiniC, FieschiC, FerdinandoD. 1999. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neur Sci, 168:131–136.
3.
BonettiP, DiodatiG, DragoC, CasarinC, ScaccabarozziS, RealdiG, RuolA, AlbertiA. 1994. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2αJ Hepatol, 20:416–420.
4.
BrandCM, LeadbeaterL, BellatiG, MarottaF, IdeoO. 1993. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-α sub-types. J Interferon Res, 13:121–125.
5.
CasatoM, LaganaB, AntonelliG, DianzaniF, BonomoL. 1991. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood, 78,12:3142–3147.
6.
IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. 1996. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b. Neurology, 47:889–894.
7.
LiaoMJ, AxelrodHR, KuchlerM, YipYK, KirkbrightE, TestaD. 1992. Absence of neutralizing antibodies to interferon in condyloma acuminata and cancer patients treated with natural human leukocyte interferon. JID, 165:757–760.
8.
MilellaM, AntonelliG, SantantonioT, CurrentiM, MonnoL, MarianoN, AngaranoG, DianzaniF, PastoreG. 1993. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver, 13:146–150.
9.
ObergK, AlmG. 1997. The Incidence and clinical significance of antibodies to interferon-a in patients with solid tumors. Biotherapy, 10:1–5.
10.
PanitchH, GoodinDS, FrancisG, ChangP, CoylePK, O'ConnorP, MonaghanE, LiD, WeinshenkerB. 2002. Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE trial. Neurology, 59:1496–1506.
11.
PorresJC, CarrenoV, RuizM, MarronJA, BartolomeJ. 1989. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatology, 8:351–357.
12.
PRISMS Study Group and University of British Columbia MS/MRI Analysis Group. 2001. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology, 56:1628–1636.
RoffiL, MelsGC, AntonelliG, BellatiG, PanizzutiF, PipernoA, PozziM, RavizzaD, AngeliG, DianzaniF, ManciaG. 1995. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology, 21:645–649.
15.
RossC, EnglerCB, SanderB, BendtzenK. 2002. IFN-α antibodies in patients with age-related macular degeneration treated with recombinant human IFN-α2a. J Interferon Cytokine Res, 22:421–426.
16.
RudickRA, SimonianNA, AlamJA, CampionM, ScaramucciJO, JonesW, CoatsME, GoodkinDE, Weinstock-GuttmanB, HerndonRM. and others. 1998. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology, 50:1266–1272.
17.
RussoD, CandoniA, ZuffaE, MinisiniR, SilvestriF, FaninR, ZajaF, MartinelliG, TuraS, BottaG, BaccaraniM. 1996. Neutralizing anti-interferon-α antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (α2a) and lymphoblastoid interferon-αBr J Haematol, 94:300–305.
18.
SantantonioT, MilellaM, AntonelliG, ScagnolariC. 2006. Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon. J Hepatol, 45:758–761.
19.
ShermanK, BaconB, FeinmanV, JeffersJ. Alferon Cooperative Study Group. 1999. Efficacy of interferon alfa-n3 vs. recombinant interferon in the treatment of chronic hepatitis C virus infection: a multicenter, randomized trial. Poster at the American College of Gastroenterology Annual Meeting.
20.
SkillmanDR, MaloneJL, DeckerCF, WagnerKF, MapouRL, LiaoMJ, TestaD, MeltzerMS. 1996. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity. JID, 173:1107–1114.
21.
SteisRG, LongoDL. 1994. Clinical relevance of recombinant interferon-α2a antibodies in patients with hairy cell leukemia. J Interferon Res, 14:207–209.
22.
TefferiA, GrendahlDC. 1996. Natural leukocyte interferon-α therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-αAm J Hematol, 52:231–233.
23.
van der EijkAA, VrolijkJM, HaagmansBL. 2006. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. NEJM, 354:1323–1324.
24.
von WussowP, FreundM, BlockB, DiedrichH, PoliwodaH, DeicherH. 1987. Clinical significance of anti-IFN-α antibody titres during interferon therapy. Lancet, 12:635–636.
25.
von WussowP, PralleH, HochkeppelHK, JakschiesD, SonnenS, SchmidtH, Muller-RosenauD, FrankeM, HaferlachT, ZwingersT, RappU, DeicherH. 1991. Effective natural interferon-α therapy in recombinant interferon-α-resistant patients with hairy cell leukemia. Blood, 78:38–43.
26.
ZhaoX-X, HuaJ, SmithT, Ferencz-BiroK, LiaoJ-J, RashidbaigiA. 1997. Interferon-α neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-αn3. Hum Antibodies, 8,3:129–136.
